Ankylosing spondylitis: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett |
imported>Caesar Schinas m (Bot: Replacing medical templates with CZMed) |
||
| Line 3: | Line 3: | ||
==Treatment== | ==Treatment== | ||
Inhibitors of [[tumor necrosis factor-alpha]] can benefit according to a [[meta-analysis]].<ref name="pmid17651658">{{cite journal |author=McLeod C, Bagust A, Boland A, ''et al'' |title=Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation |journal=Health Technol Assess |volume=11 |issue=28 |pages=1–158, iii–iv |year=2007 |month=August |pmid=17651658 |doi= |url=http://www.hta.ac.uk/execsumm/summ1128.htm |issn=}}</ref> For example, TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of [[tumor necrosis factor-alpha]].<ref>{{ | Inhibitors of [[tumor necrosis factor-alpha]] can benefit according to a [[meta-analysis]].<ref name="pmid17651658">{{cite journal |author=McLeod C, Bagust A, Boland A, ''et al'' |title=Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation |journal=Health Technol Assess |volume=11 |issue=28 |pages=1–158, iii–iv |year=2007 |month=August |pmid=17651658 |doi= |url=http://www.hta.ac.uk/execsumm/summ1128.htm |issn=}}</ref> For example, TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of [[tumor necrosis factor-alpha]].<ref>{{CZMed|Etanercept}}</ref> and may help patients with ankylosing spondylitis.<ref name="pmid11986408">{{cite journal |author=Gorman JD, Sack KE, Davis JC |title=Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha |journal=N. Engl. J. Med. |volume=346 |issue=18 |pages=1349–56 |year=2002 |month=May |pmid=11986408 |doi=10.1056/NEJMoa012664 |url=http://content.nejm.org/cgi/content/full/346/18/1349 |issn=}}</ref><ref name="pmid17934088">{{cite journal |author=Furst DE, Breedveld FC, Kalden JR, ''et al'' |title=Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 |journal=Ann. Rheum. Dis. |volume=66 Suppl 3 |issue= |pages=iii2–22 |year=2007 |month=November |pmid=17934088 |doi=10.1136/ard.2007.081430 |url=http://ard.bmj.com/cgi/pmidlookup?view=long&pmid=17934088 |issn=}}</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 03:04, 3 June 2009
In medicine and rheumatology, ankylosing spondylitis is an "inflammatory joint disease affecting the spine. It occurs predominantly in young males and produces pain and stiffness as a result of inflammation of the sacroiliac, intervertebral, and costovertebral joints. Etiology is unknown."[1][2]
Treatment
Inhibitors of tumor necrosis factor-alpha can benefit according to a meta-analysis.[3] For example, TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of tumor necrosis factor-alpha.[4] and may help patients with ankylosing spondylitis.[5][6]
References
- ↑ Anonymous (2024), Ankylosing spondylitis (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Braun J, Sieper J (April 2007). "Ankylosing spondylitis". Lancet 369 (9570): 1379–90. DOI:10.1016/S0140-6736(07)60635-7. PMID 17448825. Research Blogging.
- ↑ McLeod C, Bagust A, Boland A, et al (August 2007). "Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation". Health Technol Assess 11 (28): 1–158, iii–iv. PMID 17651658. [e]
- ↑ The most up-to-date information about Etanercept and other drugs can be found at the following sites.
- Etanercept - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Etanercept - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Etanercept - Detailed information from DrugBank.
- ↑ Gorman JD, Sack KE, Davis JC (May 2002). "Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha". N. Engl. J. Med. 346 (18): 1349–56. DOI:10.1056/NEJMoa012664. PMID 11986408. Research Blogging.
- ↑ Furst DE, Breedveld FC, Kalden JR, et al (November 2007). "Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007". Ann. Rheum. Dis. 66 Suppl 3: iii2–22. DOI:10.1136/ard.2007.081430. PMID 17934088. Research Blogging.